about
In vitro and in vivo models for the study of oral delivery of nanoparticlesApplications of stable isotopes in clinical pharmacologyTaking the lead from our colleagues in medical education: the use of images of the in-vivo setting in teaching concepts of pharmaceutical science.Polylactide-co-glycolide nanoparticles of antitubercular drugs: formulation, characterization and biodistribution studies.Experimental design for the formulation and optimization of novel cross-linked oilispheres developed for in vitro site-specific release of Mentha piperita oil.A Review of Disintegration Mechanisms and Measurement Techniques.Gastric emptying of non-disintegrating solid drug delivery systems in fasted state: relevance to drug dissolution.Biomagnetic methods: technologies applied to pharmaceutical research.Gastroretentive dosage forms: a review with special emphasis on floating drug delivery systems.A review of imaging methods for measuring drug release at nanometre scale: a case for drug delivery systems.Dissolution testing of oral modified-release dosage forms.Decades of research in drug targeting to the upper gastrointestinal tract using gastroretention technologies: where do we stand?Analysis of factors influencing gastric emptying of pellets in a fed state.Proof-of-concept study on the suitability of 13C-urea as a marker substance for assessment of in vivo behaviour of oral colon-targeted dosage forms.Novel orally swallowable IntelliCap(®) device to quantify regional drug absorption in human GI tract using diltiazem as model drug.A novel approach in distinguishing between role of hydrodynamics and mechanical stresses similar to contraction forces of GI tract on drug release from modified release dosage forms.Study on of bioadhesive property of carbomer 934 by a gamma camera in vivoGastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulationRadiolabeling and dose fixation study of oral alpha-ketoglutarate as a cyanide antidote in healthy human volunteers.Assessment of nevirapine bioavailability from targeted sites in the human gastrointestinal tract.A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules.Accessibility of solid core tablet for dissolution in an asymmetric triple-layer matrix system.Plasma pharmacokinetics and gastrointestinal transit of a new propionyl-L-carnitine controlled release formulation.In vivo disintegration profiles of encapsulated and nonencapsulated sumatriptan: gamma scintigraphy in healthy volunteers.Novel modulation of drug delivery using binary zinc-alginate-pectinate polyspheres for zero-order kinetics over several days: experimental design strategy to elucidate the crosslinking mechanism.Determination of intraluminal theophylline concentrations after oral intake of an immediate- and a slow-release dosage form.Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis.TARGIT technology: coated starch capsules for site-specific drug delivery into the lower gastrointestinal tract.Optimization of LY545694 tosylate controlled release tablets through pharmacoscintigraphy.Gastrointestinal transit of model mini-tablet controlled release oral dosage forms in fasted human volunteers.Analysis of the meal-dependent intragastric performance of a gastric-retentive tablet assessed by magnetic resonance imaging.Wireless EndoscopyFloating microspheres: a review
P2860
Q26829514-19FF8755-B362-42E9-AE4C-E9AACF5547DCQ28740996-3860EC70-DDA6-4C23-8D00-7E6EFC728978Q33909963-F8E040D6-479C-45C6-86C2-B1648395AE4EQ35532338-7689D99E-4354-4EE0-B20E-9DC94098DCD0Q37444882-3B083FD1-B415-4D0F-B46A-3DD3C1439F41Q37739106-3E70E00F-1145-46BD-858F-BC8985F99CEBQ37768454-36B56AB7-5AAF-4B20-A4B8-A75442D7B62BQ37800414-7C2EC395-689B-42F9-86DC-AF3F2361C91CQ37801383-C37CDF6D-4310-4520-AC35-58477BF7E1A2Q37974934-1C205983-6929-4D37-AF58-97BADF5E7B5FQ38017706-342746AE-DA14-48EC-8874-E8AB161E77F0Q38229749-2209E4B9-BE8C-4A84-A2F2-B2B8E13E927BQ41061087-3587817B-DEE9-4369-9793-B8DC7696BB43Q41825771-55569285-3E1C-4348-A015-EDBD8E691E35Q41884689-06A14283-2A52-471D-B37B-F65BD86F7057Q42155360-72484B4E-E7DC-4217-B232-0DDD3C7B1E27Q42156048-C0D7AE0D-0ABE-4B45-BEB0-AD0C871721CEQ42758588-AA2CA6F5-E3D2-4001-962E-D11AF0971962Q43007786-D18D4B5D-207E-4388-A929-4713373EA5F0Q43268966-40CE5FE1-7C6B-4309-B4AC-3E594C9D9DE4Q44352713-030C9DEA-9510-4BBA-80ED-C5B313974CD7Q44648345-1EE2AA8E-7A2C-47D8-9DC0-9836E8DE52ABQ45061214-BA620558-9141-471E-91B4-0989872E4319Q45188840-AB94F778-FEB2-47D1-8045-B450F48B72CDQ46385830-CAAD7440-9CE7-483B-91F9-892F0FF5DE9FQ46651828-E7095D3B-7AEA-4CBD-BB99-EEBFDBB112BCQ46674905-AFA64745-C527-47EC-A1C2-AEB2D84D2A84Q46810701-466E1046-581A-4E7D-8EE7-11000FD38833Q47626440-438A4B90-7771-4518-8EC8-6294C75F83E0Q51467403-AE8FC0BF-003F-4527-BC83-2C4FF11EBAACQ51820281-87DC5687-F538-4B98-80AB-B1A2E3CFF8FBQ57275675-8D9D342E-F491-4CE9-A7EB-C8EBCC9C4DC6Q57382042-0AAC6155-F732-46EC-81F2-952F4A1DEEFB
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The role of gamma-scintigraphy in oral drug delivery.
@ast
The role of gamma-scintigraphy in oral drug delivery.
@en
The role of gamma-scintigraphy in oral drug delivery.
@nl
type
label
The role of gamma-scintigraphy in oral drug delivery.
@ast
The role of gamma-scintigraphy in oral drug delivery.
@en
The role of gamma-scintigraphy in oral drug delivery.
@nl
prefLabel
The role of gamma-scintigraphy in oral drug delivery.
@ast
The role of gamma-scintigraphy in oral drug delivery.
@en
The role of gamma-scintigraphy in oral drug delivery.
@nl
P2093
P1476
The role of gamma-scintigraphy in oral drug delivery.
@en
P2093
P304
P356
10.1016/S0169-409X(00)00135-6
P407
P577
2001-03-01T00:00:00Z